Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine, Indomethacin and Zithromax in mild COVID-19
NCT04344457Phase 2Unknown
- Sponsor
- Perseverance Research Center
- Start
- Apr 2020
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hydroxychloroquine, indomethacin and azithromycin in coronavirus disease 2019 (COVID-19), sponsored by Perseverance Research Center. Primary endpoint: Improvement of clinical status up to 28 days. Status: unknown.
02
Drugs
hydroxychloroquineindomethacinazithromycin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04344457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04344457.